Quality of Life Kinoko Platinum AHCC 750 Mg 60 Ct by Quality of Life

Product Information

All patients enrolled were included in safety analysis for adverse events. Overall, no study patients reported greater than grade 1 toxicity on either placebo or the AHCC supplement arm. AHCC was well tolerated compared to placebo. The proprietary, standardized extract of cultured Lentinula edodes mycelia, AHCC (Amino Up Chemical Co. Ltd, Sapporo, Japan), was developed in Japan in 1992. Several studies have reported a variety of therapeutic effects, including antioxidant and anticancer activity and improvement of immune response ( 9, 10). In animal studies, AHCC has shown the ability to treat and prevent cancer, and modulate the immune system to prevent infectious processes ( 9– 11). Gao et al. demonstrated the immunomodulating effects of AHCC in a study that showed enhanced antigen (Ag) activation of CD4 (+) and CD8 (+) T cells, and the increased frequency of tumor Ag-specific IFN-gamma producing CD8 (+) T cells as well as increases in cell numbers of NK cells and gamma delta T cells ( 10). In clinical studies AHCC has demonstrated benefit to decrease risk of infection and ameliorate symptoms of existing infections ( 9– 11, 13). Since studies have demonstrated AHCC induces apoptosis ( 12– 14), it is possible that AHCC may also prevent/delay tumor growth regardless of the role of HR-HPV. Now, AminoUp has begun a collaboration with the University of Texas Medical Branch, to assess whether AHCC could assist with global efforts to fight the SARS-CoV-2 virus through supporting the immune system. If you have problems sleeping or experience digestive issues with this product you are taking too much. Reduce the dose to one capsule per day to let your body get used to the product and gradually build up to the required dosage. Everyone is different and whilst some people can take 6 capsules in one dose, others with sensitive digestive systems need to take their time and build up to the required dose. The human papillomavirus (HPV) is classified as a non-enveloped, double-stranded DNA virus that generally infects the epithelial layer of cells including cutaneous and mucosal surfaces and is associated with benign warts, carcinoma in situ, and malignant lesions ( 1, 2). There are over 100 HPV strains identified in humans, 40 low-risk HPV (LR-HPV) strains associated with genital warts/lesions, and fifteen high-risk HPV (HR-HPV) strains associated with cancer. When HR-HPV infections persist over time, patients have an increased risk of developing cancer ( 3). However, it should be noted that having a persistent high-risk HPV infection does not cause cancer by itself; rather, it is a contributing co-factor in the risk for development of cancer when it occurs in combination with other insults such as poor nutrition, smoking, physiological stress, or immune dysfunction/suppression. In the United States, there are an estimated 85,890 cases of cancer caused by persistent high-risk HPV infections, and an estimated 79 million Americans are infected with HPV today ( 4, 5).

Results: Fifty women with high-risk HPV were enrolled, and 41 completed the study. Fourteen (63.6%) of the 22 patients in the AHCC supplementation arm were HPV RNA/HPV DNA negative after 6 months, with 64.3% (9/14) achieving a durable response defined as being HPV RNA/HPV DNA negative 6 months off supplementation. On the placebo arm, two (10.5%) of 19 patients were HPV negative at 12 months. In the twelve placebo arm patients who elected to continue on the unblinded study, 50% (n = 6) were HPV RNA/HPV DNA negative after 6 months of AHCC supplementation. At the time of completion of the study, there were a total of 34 patients (22 blinded and 12 unblinded) who had received AHCC supplementation with an overall response rate of 58.8% that cleared HPV persistent infections. At the time of enrollment, the mean IFN-β level was 60.5 ± 37.6 pg/ml in women with confirmed persistent HPV infections. Suppression of IFN-β to less than 20 pg/ml correlated with an increase in T lymphocytes and IFN-γ and durable clearance of HPV infections in women who received AHCC supplementation.Methods: Cervical cancer cells, CaSki (HPV16 +), HeLa(HPV18 +), SiHa(HPV16/18 +), and C-33A(HPV −), were treated in vitro with AHCC 0.42 mg/mL daily x7 days then observed x7 days with daily sample collection. A confirmatory study in cervical cancer mouse models, SiHa(HPV16/18 +) and C-33A(HPV −), was conducted: mice were divided into three groups per cell line then dosed with AHCC 50 mg/kg/d ( N = 10), or vehicle alone ( N = 10), or no supplementation ( N = 10) for a total of 90 days followed by 30 days of observation. Tumors were measured 3x/week and blood samples collected bi-weekly to evaluate interferon (IFN) alpha(α), beta(β), and gamma(γ) and immunoglobulin G(IgG) by immunoassays. Tumors were evaluated for HR-HPV expression by PCR. Two pilot studies of 10 patients each were conducted in women with confirmed persistent HR-HPV+ infections. The 1 st study evaluated AHCC 3g from 5 weeks up to 6 months and 2nd study evaluated AHCC 1g < 8 months. HR-HPV DNA status and the immune panel were monitored at each visit. It is a mouse-model study. Mice are going to be infected with SARS-CoV-2 virus and we will examine the mortality change and other parameters with and without AHCC administration,” says Homma. JS served as principal investigator of the clinical trial and was responsible for study concept, protocol design, data analysis, clinical interpretation of data, writing, and finalization of the manuscript. AG, LM, and BR served as the primary research team responsible for patient screening, clinic visits, sample collection, and analysis and participated in the writing and review of the manuscript. JF served as a clinical collaborator on this study and participated in protocol design, clinical interpretation of data, and final review of the manuscript. JL served as a clinical collaborator on this study and participated in the clinical interpretation of the data and final review of the manuscript. YB served as a research collaborator participating in the interpretation of the sample of analysis, protocol design, and review of the final manuscript. RO served as a research collaborator participating in the interpretation of the sample of analysis and implications for future monitoring assays. He participated in the review and finalization of the manuscript. TB served as a clinical collaborator on this study and participated in protocol design, clinical interpretation of data, and final review of the manuscript. All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication. Funding

History of myocardial infarction within past 6 months, unstable angina, CHF, or uncontrolled hypertension (>140/90). Patients with significant medical comorbidities at the discretion of the primary gynecologist. Including immunosuppressive conditions (i.e., HIV+ and rheumatoid arthritis) or taking immune modulation mediations (i.e., immunosuppressants). AHCC induces our natural defence, so does not go through the same mechanism as an antibiotic. Therefore, resistance should not be a problem,” says Homma. A) AHCC 3g supplementation (B) AHCC 1g supplementation. IFN-β is a Type-1 IFN often associated with virulence of chronic viral infections. Chronic viral infections are often associated with high levels of IFN-β that leads to suppression of the production of IFN-γ and NK/T-cell cytotoxic cell immunity. It was observed in both pilot studies AHCC supplementation suppression of host IFN-β levels below level of 25 pg/mL that lead to modulation of the cytotoxic cell immunity to a successful, durable clearance of persistent, high risk HR-HPV infections.These statements have not been evaluated by any official health authority. These products are not intended to diagnose, treat, cure, or prevent any disease. The stained cells were acquired using LSR II (BD Biosciences), and Diva software was used for analysis. With the use of forward and side scatter, the lymphocyte population was gated on low side scatter and CD45 bright population while acquiring the 50,000 gated events. The NK cell population was then identified as (CD3 negative, CD 2, CD56C, and CD7 positive) cells. The percent of T cells and NK cells from the lymphocyte gate was obtained for the final analysis. Statistical Analysis Objective: To determine the efficacy, safety, and durability of the use of AHCC supplementation for 6 months to support the host immune system to clear high-risk human papillomavirus (HPV) infections. The AHCC supplement is a proprietary, standardized extract of cultured lentinula edodes mycelia (AHCC ®, Amino Up, Ltd., Sapporo, Japan) that has been shown to have unique immune modulatory benefits. This was the first double-blind, placebo-controlled clinical study to demonstrate that the nutritional supplement, AHCC, is effective in eliminating persistent, high-risk HPV infections with durable response in those patients who achieved an IFN-β level below 20 pg/ml. Overall, AHCC was well tolerated and had comparable adverse effects as compared to placebo. A) The C-33A (HPV-) and SiHa(HPV 16/18+) human cervical cancer cell lines were supplemented in vitro with a one-time dose of AHCC 0.42 mg/mL and then incubated for 72 h. The study was completed in duplicate as described in materials and methods. While HR-HPV was suppressed for 24 h, it was not cleared evident by expression at 48 and 72 h. NT, non-treatment control. (B) The C-33A (HPV-) and SiHa(HPV16/18+) human cervical cancer cell lines were supplemented in vitro with daily fresh dose of AHCC 0.42 mg/mL once every 24 h for 5 days (120 h) as described in materials and methods. NT, non-treatment control. This was successful to eliminate HR-HPV expression in the SiHa cell line.